Medicus Pharma Pivots SkinJect to Gorlin Syndrome, Drops nBCC Development
MDCX sits 16% above its 52-week low of $0.144.
Summary
Medicus Pharma is narrowing SkinJect development exclusively to Gorlin syndrome, abandoning sporadic/nodular basal cell carcinoma. The decision follows FDA feedback that BCC in Gorlin is the same disease as sporadic BCC, complicating orphan drug designation. The company cites a commercial assessment projecting $25,800 per treatment, a $1.1B TAM, and $383M peak revenue. This pivot concentrates resources on a rare-disease path with potential orphan exclusivity and a priority review voucher, but the FDA has not granted designations. The move aligns with the September 8 capital-efficiency strategy and follows the Pfizer CD228V licensing deal, signaling a focus on high-value rare indications.
At the time of this announcement, MDCX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.14 to $3.05. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.